Literature DB >> 32550983

PROTAC Compounds Targeting α-Synuclein Protein for Treating Neurogenerative Disorders: Alzheimer's and Parkinson's Diseases.

Robert B Kargbo1.   

Abstract

Entities:  

Year:  2020        PMID： 32550983      PMCID： PMC7294559          DOI： 10.1021/acsmedchemlett.0c00192

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  5 in total

1.  New therapeutic approaches to target alpha-synuclein in Parkinson's disease: The role of immunotherapy.

Authors:  T Fernández-Valle; I Gabilondo; J C Gómez-Esteban
Journal:  Int Rev Neurobiol       Date:  2019-07-18       Impact factor: 3.230

Review 2.  Targeting α-Synuclein in Parkinson's Disease: Progress Towards the Development of Disease-Modifying Therapeutics.

Authors:  Daniel Savitt; Joseph Jankovic
Journal:  Drugs       Date:  2019-06       Impact factor: 9.546

Review 3.  Immunotherapies in Huntington's disease and α-Synucleinopathies.

Authors:  Oluwaseun Fatoba; Yosuke Ohtake; Takahide Itokazu; Toshihide Yamashita
Journal:  Front Immunol       Date:  2020-02-25       Impact factor: 7.561

Review 4.  Targeting Alpha-Synuclein as a Therapy for Parkinson's Disease.

Authors:  Carroll Rutherford Fields; Nora Bengoa-Vergniory; Richard Wade-Martins
Journal:  Front Mol Neurosci       Date:  2019-12-05       Impact factor: 5.639

Review 5.  Immunotherapy for Parkinson's disease.

Authors:  Aaron D Schwab; Mackenzie J Thurston; Jatin Machhi; Katherine E Olson; Krista L Namminga; Howard E Gendelman; R Lee Mosley
Journal:  Neurobiol Dis       Date:  2020-01-21       Impact factor: 5.996
  5 in total
  7 in total

1.  PROTACs technology for treatment of Alzheimer's disease: Advances and perspectives.

Authors:  Hiroyuki Inuzuka; Jing Liu; Wenyi Wei; Abdol-Hossein Rezaeian
Journal:  Acta Mater Med       Date:  2022-01-21

Review 2.  Scrutinizing the Therapeutic Potential of PROTACs in the Management of Alzheimer's Disease.

Authors:  Shiveena Bhatia; Manjinder Singh; Tanveer Singh; Varinder Singh
Journal:  Neurochem Res       Date:  2022-08-20       Impact factor: 4.414

Review 3.  PROTACs: great opportunities for academia and industry (an update from 2020 to 2021).

Authors:  Ming He; Chaoguo Cao; Zhihao Ni; Yongbo Liu; Peilu Song; Shuang Hao; Yuna He; Xiuyun Sun; Yu Rao
Journal:  Signal Transduct Target Ther       Date:  2022-06-09

Review 4.  The Emerging Roles of E3 Ligases and DUBs in Neurodegenerative Diseases.

Authors:  Na Liu; Miao-Miao Lin; Yan Wang
Journal:  Mol Neurobiol       Date:  2022-10-19       Impact factor: 5.682

Review 5.  Crosstalk between Gut and Brain in Alzheimer's Disease: The Role of Gut Microbiota Modulation Strategies.

Authors:  Umair Shabbir; Muhammad Sajid Arshad; Aysha Sameen; Deog-Hwan Oh
Journal:  Nutrients       Date:  2021-02-21       Impact factor: 5.717

Review 6.  Challenges in Discovering Drugs That Target the Protein-Protein Interactions of Disordered Proteins.

Authors:  Judit Oláh; Tibor Szénási; Attila Lehotzky; Victor Norris; Judit Ovádi
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

Review 7.  Chemical-Mediated Targeted Protein Degradation in Neurodegenerative Diseases.

Authors:  Soonsil Hyun; Dongyun Shin
Journal:  Life (Basel)       Date:  2021-06-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.